NCT06352541View on ClinicalTrials.gov

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Healthy

Interventions

DRUG

PRO-232

Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%

OTHER

Placebo

Vehicle Control, ophthalmic solution

All Listed Sponsors

lead

Laboratorios Sophia S.A de C.V.

INDUSTRY